Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR1 | Q9Y271 | 10/20 | 1.00 |
| ▸ | CYSLTR2 | Q9NS75 | 5/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | THPO | P40225 | 1/20 | 0.56 |
| ▸ | BLM | P54132 | 1/20 | 0.56 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10685299 | 0.89 | CYSLTR1 (0.80) | CYSLTR1CYSLTR2PDE10A | |
| SCHEMBL10755026 | 0.84 | CYSLTR1 (0.72) | CYSLTR1CYSLTR2KDM4EMEN1NPC1 | |
| SCHEMBL10377922 | 0.83 | CYSLTR1 (0.72) | CYSLTR1CYSLTR2KDM4EMEN1NPC1 | |
| SCHEMBL10655893 | 0.83 | CYSLTR1 (0.70) | CYSLTR1CYSLTR2KDM4EMEN1NPC1 | |
| Hydrochloric Acid SCHEMBL9447146 | 0.82 | CYSLTR1 (0.69) | CYSLTR1CYSLTR2KDM4EMEN1NPC1 | |
| SCHEMBL9721977 | 0.81 | CYSLTR1 (0.69) | CYSLTR1CYSLTR2KDM4EMEN1NPC1 | |
| SCHEMBL14021761 | 0.81 | CYSLTR1 (0.68) | CYSLTR1CYSLTR2GPBAR1PDE10A | |
| SCHEMBL10375899 | 0.81 | CYSLTR1 (0.68) | CYSLTR1CYSLTR2GPBAR1 | |
| SCHEMBL9447225 | 0.81 | CYSLTR1 (0.67) | CYSLTR1CYSLTR2KDM4EMEN1NPC1 | |
| SCHEMBL9715790 | 0.81 | CYSLTR1 (0.67) | CYSLTR1CYSLTR2KDM4EMEN1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 546 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1931320-B1 | MICROPARTICLES WITH MODIFIED RELEASE OF AT LEAST ONE ACTIVE PRINCIPLE AND ORAL DOSAGE FORM COMPRISING THE SAME | FLAMEL IRELAND LTD (IE) | 2022-06-15 | — | — | EP | claimed |
| EP-2575786-B1 | PROCESS FOR DRY POWDER FORMULATIONS | SIMA PATENT VE LISANSLAMA HIZMETLERI LTD STI (TR) | 2017-11-15 | — | — | EP | claimed |
| US-9259376-B2 | Process for dry powder formulations | SIMA PATENT VE LISANSLAMA HIZMETLERI LTD. STI. (TR) | 2016-02-16 | — | — | US | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-20130202778-A1 | PROCESS FOR DRY POWDER FORMULATIONS | SIMA PATENT VE LISANSLAMA HIZMETLERI LTD. STI. (TR) | 2013-08-08 | — | — | US | claimed |
| EP-2575786-A2 | PROCESS FOR DRY POWDER FORMULATIONS | Bilgic, Mahmut (TR) | 2013-04-10 | — | — | EP | claimed |
| EP-2563364-A1 | COMBINATION OF CARMOTEROL AND FLUTICASONE FOR USE IN THE TREATMENT RESPIRATORY DISEASES | Bilgic, Mahmut (TR) | 2013-03-06 | — | — | EP | claimed |
| WO-2013009271-A1 | NEW IMPROVED DRY POWDER FORMULATION | BILGIC MAHMUT (TR) | 2013-01-17 | — | — | WO | claimed |
| US-8268352-B2 | Modified release composition for highly soluble drugs | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-18 | — | — | US | claimed |
| US-8263125-B2 | Dosage form for high dose-high solubility active ingredients that provides for immediate release and modified release of the active ingredients | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-11 | — | — | US | claimed |
| WO-2007036671-A2 | MICROPARTICLES WITH MODIFIED RELEASE OF AT LEAST ONE ACTIVE PRINCIPLE AND ORAL GALENIC FORM COMPRISING SAME | FLAMEL TECHNOLOGIES (FR) | 2007-04-05 | — | — | WO | claimed |
| US-20060024365-A1 | Novel dosage form | VAYA NAVIN | 2006-02-02 | — | — | US | claimed |
| US-20060018933-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-20060018934-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-20030176421-A1 | PROKINETIC AGENTS FOR TREATING GASTRIC HYPOMOTILITY AND RELATED DISORDERS | WATSON JOHN W (US) | 2003-09-18 | — | — | US | claimed |
| EP-1336602-A1 | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases | Scaramuzzino, Giovanni (IT) | 2003-08-20 | — | — | EP | claimed |
| EP-0469477-B1 | Antiallergic combination | HOFFMANN LA ROCHE (CH) | 1995-09-20 | — | — | EP | claimed |
| EP-0469477-A1 | Antiallergic combination | F. HOFFMANN-LA ROCHE AG (CH) | 1992-02-05 | — | — | EP | claimed |
| EP-0232954-A2 | Heterocyclic sulphonamides | AMERICAN HOME PRODUCTS CORPORATION (US) | 1987-08-19 | — | — | EP | claimed |
| US-4675405-A | Quinoline compounds as antiallergic and antithrombotic agents | AMERICAN HOME PRODUCTS CORPORATION (US) | 1987-06-23 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176421-A1 | PROKINETIC AGENTS FOR TREATING GASTRIC HYPOMOTILITY AND RELATED DISORDERS | OPRM1, OPRK1, OPRD1 | CYSLTR1 4303/4885CYSLTR2 3991/4885KDM4E 1698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.